Latest news with #EVOICL
Associated Press
4 days ago
- Health
- Associated Press
Waring Vision Institute Surpasses 1,000 Five-Star Google Reviews
Affirms status as South Carolina's most trusted name in vision correction Waring Vision Institute, a premier destination for advanced vision correction in South Carolina, proudly announces a major milestone: more than 1,000 five-star Google reviews from patients across the region and beyond. This achievement underscores the institute's ongoing commitment to clinical excellence, personalized care, and transformative outcomes in ophthalmology. Known for offering innovative procedures—including SMILE, LASIK, EVO ICL, CLEAR, and advanced cataract surgery—Waring Vision Institute continues to set the standard in eye care. Led by world-renowned refractive surgeon Dr. George O. Waring IV, the practice also includes a distinguished team of specialists: Dr. Michael DeCourcey, Dr. Leslie Scarlett, and Dr. Ellesse Boiwka, each contributing deep expertise and compassionate care across various subspecialties. 'Reaching 1,000 five-star reviews is not just a number—it's a reflection of the meaningful relationships we build with our patients every day,' said Dr. Waring. 'Our team is deeply honored by the trust our community continues to place in us.' Patients frequently highlight the institute's blend of cutting-edge technology, seamless experience, and warm, attentive staff. The reviews reflect voices from all walks of life—teachers, athletes, surgeons, retirees, and students—all sharing stories of restored clarity and renewed confidence. With this milestone, Waring Vision Institute is believed to be among the highest-rated medical practices in South Carolina on Google. This recognition adds to a long list of industry firsts, including: These achievements reinforce the institute's position as a consistent innovator and leader in the field of vision correction. About Waring Vision Institute Waring Vision Institute, based in Mount Pleasant, South Carolina, specializes in advanced vision correction procedures, including LASIK, laser cataract surgery, EVO ICL, and a range of aesthetic services. Led by Dr. George O. Waring IV, alongside Dr. Michael DeCourcey, Dr. Leslie Scarlett, and Dr. Ellesse Boiwka, the institute delivers exceptional patient outcomes through cutting-edge innovation, clinical expertise and a deep commitment to personalized care. For more information, visit Media Contact Jessica Stubing [email protected] ### SOURCE: Waring Vision Institute Copyright 2025 EZ Newswire
Business Insider
5 days ago
- Business
- Business Insider
Staar Surgical Stock (STAA) Soars on $1.5B Alcon Deal
Staar Surgical (STAA) stock soared on Tuesday after the implantable lenses company reached an agreement with eye care company Alcon (ALC). This will have Alcon acquire all outstanding shares of STAA stock for $28 per share in cash. This represents a 51% premium to the stock's prior closing price and has a total equity value of approximately $1.5 billion. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Stephen Farrell, CEO of Staar Surgical, said, 'As a significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide.' Staar Surgical and Alcon expect the deal to close within six to 12 months. It already has the support of both companies' boards of directors. Alcon also expects the deal to be accretive to its earnings in the second year after the deal is complete. Staar Surgical Stock Movement Today Staar Surgical stock was up 44.73% in pre-market trading on Tuesday, following a 4.11% rally yesterday. However, the shares have fallen 23.88% year-to-date and 51.2% over the past 12 months. Today's news came with heavy trading, as some 8 million shares changed hands, compared to a three-month daily average of about 678,000 units. Is Staar Surgical Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Staar Surgical is Hold, based on two Buy, two Hold, and a single Sell rating over the past three months. With that comes an average STAA price target of $19.29, representing a potential 4.33% upside for the shares.
Yahoo
01-08-2025
- Business
- Yahoo
STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025
LAKE FOREST, Calif., August 01, 2025--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results WebcastDate: Wednesday, August 6, 2025Time: 4:30 p.m. ETLocation: The live webcast, including an option to pre-register, can be accessed at the preceding link or the "Investors" section of the STAAR website at A webcast replay will be available at the same link for at least 90 days. About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at View source version on Contacts InvestorsNiko Liu, CFAUnited States: 626-303-7902 ext 3023Hong Kong: +852-6092-5076nliu@ investorrelations@ Sign in to access your portfolio
Yahoo
11-06-2025
- Health
- Yahoo
Houston LASIK & Eye Launches EVO ICL: The Latest Innovation for Patients with Thin Corneas
Houston, June 11, 2025 (GLOBE NEWSWIRE) -- Houston, Texas - HOUSTON, TX – Houston LASIK & Eye, a globally recognized center for laser vision correction, is proud to announce the addition of EVO ICL (Implantable Collamer Lens) to its comprehensive selection of vision correction solutions. This revolutionary technology offers new hope for patients with thin corneas, severe refractive errors, and dry eye who previously were not candidates for traditional procedures like LASIK. Unlike LASIK, which reshapes the cornea to correct nearsightedness, farsightedness, and astigmatism, EVO ICL involves implanting a biocompatible, collagen-based lens between the iris and the natural lens through a tiny incision. This procedure preserves the corneal tissue while delivering exceptional visual outcomes, representing a notable advancement in vision correction technology. "We're thrilled to bring EVO ICL to our patients in Houston and beyond," said Dr. Amjad Khokhar, Medical Director at Houston LASIK & Eye. "This technology combines the long-term results of LASIK with the removability of contact lenses, offering an ideal solution for patients with thin corneas or chronic dry eyes who weren't candidates for traditional laser eye surgery." The EVO ICL procedure takes approximately 20-30 minutes to complete and often provides immediate vision improvement. The lens is designed to treat astigmatism from 1.0 to 4.0 diopters and nearsightedness ranging from -3.00 to -20.00 diopters. Additionally, the implant offers UV protection and reduced glare, enhancing overall visual quality. With over 2 million lenses successfully distributed worldwide and a remarkable 99% patient satisfaction rate, this technology has proven its effectiveness across diverse patient populations. The procedure itself is remarkably straightforward; after administering a topical anesthetic, your eye surgeon creates a small incision and injects the folded lens through a specialized cartridge, where it naturally unfolds to fit seamlessly in your eye. Key benefits of EVO ICL include: sharp, clear, high-definition vision, excellent night vision capabilities, no exacerbation of dry eye syndrome, rapid recovery with minimal downtime, preservation of corneal tissue, removability if needed, and built-in UV protection. Houston LASIK & Eye's adoption of EVO ICL technology aligns with its commitment to providing cutting-edge vision correction solutions. Founded in 2005 by Dr. Khokhar, the practice has established itself as a leader in ophthalmological care, attracting patients from across the United States and internationally. The center's reputation for excellence has drawn patients from every continent except Antarctica, cementing its status as a premier global destination for vision correction. Houston LASIK & Eye offers a comprehensive range of ophthalmological services, including LASIK, EVO ICL, and treatments for various eye conditions. With state-of-the-art technology and a commitment to personalized care, the practice has become a destination for patients seeking premium vision correction services. "At Houston LASIK & Eye, we believe everyone deserves access to high-quality, technologically advanced eye care," added Dr. Khokhar. "With the addition of EVO ICL, we can now help even more patients achieve freedom from glasses and contacts, regardless of corneal thickness." The best candidates for EVO ICL are individuals between 21 and 45 years old with no history of serious eye conditions or previous ophthalmic surgery. Houston LASIK & Eye offers complimentary consultations to determine candidacy for this procedure. With locations in Houston, Sugar Land, and Pearland, Houston LASIK & Eye continues to expand its services while maintaining its commitment to personalized care, advanced technology, and exceptional outcomes. For more information about EVO ICL or to schedule a consultation, please call Houston LASIK & Eye at 281-240-0478 or visit their website. ### For more information about Houston LASIK & Eye, contact the company here:Houston LASIK & EyeDr. Amjad Khokhar,(281) 240-0478info@ Southwest Freeway, Suite 350,Houston, TX 77074 CONTACT: Dr. Amjad Khokhar,
Time of India
10-06-2025
- Health
- Time of India
Pune study finds special lens implants can help patients who can't get LASIK
Pune: A 35-year-old man from US with -3 myopia, who couldn't undergo LASIK due to thin corneas and other conditions, recently underwent an advanced surgical procedure in Pune to fix his eyesight. Doctors said the patient went through an Implantable Collamer Lens (ICL) procedure, which involves surgically placing flexible lenses on the eye to correct vision problems such as myopia. His successful treatment was mentioned in a research paper on the technique by his doctors, who said it can be safely extended to people deemed unfit for LASIK. "This patient's thin cornea along with low myopia meant LASIK was out of the question," said Dr Vardhaman Kankariya, director of Asian Eye Hospital and Laser Institute and the lead investigator of the research. "He wanted to completely rid himself of his glasses so we went for what's known as EVO ICL technology, found to be effective in over 300 people with low to moderate myopia," Dr Kankariya said, adding that the lenses were earlier used to treat only high or very high myopia. "But our study showed the lenses had significant promise in patients with lower myopia as well," he said. Low myopia or patients with a 'glasses number' of less than -6 are sometimes rejected for LASIK due to thin corneas, keratoconus or severe dry eyes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo Such patients will need a pair of glasses for life. But the study, the doctors said, found that ICL implants helped these people ditch spectacles. Dr Kankariya said: "We evaluated patients with mild to moderate myopia (up to -6 diopters) and with unsuitable corneas for LASIK. All 361 evaluated patients were successfully treated with ICL implants, offering them spectacle-free vision. Our study has been peer reviewed and earned the 'Best Research Paper Award' at the Asia-Pacific Academy of Ophthalmology (APAO) annual conference that was held in Delhi in April. " The ICL procedure involves placing a thin, flexible, biocompatible lens in front of the eye's natural lens. Unlike LASIK, ICL does not require corneal thinning, does not induce dry eyes and is fully reversible, a feature the doctors said made it an ideal alternative for patients with borderline corneal parameters. Dr Shirin Sonvane, presenting author of the study, said: "The procedure takes 5 minutes, is painless and does not require anesthesia. This study gives hope to many myopia patients who earlier had no option but to depend on glasses or contact lenses." Dr Viraj Padwal, a contributor to the study said: "Traditionally, ICL was reserved for patients with high myopia, more than -8D, but this study demonstrated it is effective in lower myopia ranges as well." Dr Harshul Tak, executive committee member of the Indian Intraocular and Refractive Society said nearly 10% of those applying for LASIK are rejected due to multiple reasons. "But this study on ICL implants, for LASIK-rejected patients with low myopia, is good research. There have been very few reports of the ICL procedure on such patients in the past. This is the largest study in the world on such patients, making it a valuable reference for ophthalmologists globally," Dr Tak said.
